0001209191-22-017034.txt : 20220308 0001209191-22-017034.hdr.sgml : 20220308 20220308160318 ACCESSION NUMBER: 0001209191-22-017034 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220304 FILED AS OF DATE: 20220308 DATE AS OF CHANGE: 20220308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Daniell Richard CENTRAL INDEX KEY: 0001726096 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16174 FILM NUMBER: 22721681 MAIL ADDRESS: STREET 1: 5 BASEL STREET, PO BOX 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 4951033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 BAZEL ST STREET 2: P O B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 BUSINESS PHONE: 9729267267 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 5 BAZEL ST PO B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-04 0 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001726096 Daniell Richard C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 9644020 ISRAEL 0 1 0 0 Exec. VP, European Commercial Ordinary Shares 2022-03-04 4 M 0 15920 A 36200 D Ordinary Shares 2022-03-04 4 S 0 15920 7.4825 D 20280 D Ordinary Shares 2022-03-04 4 M 0 43358 A 63638 D Ordinary Shares 2022-03-04 4 S 0 20456 7.4825 D 43182 D Ordinary Shares 2022-03-05 4 M 0 22576 A 65758 D Ordinary Shares 2022-03-07 4 S 0 22576 7.3667 D 43182 D Restricted Share Units 2022-03-04 4 M 0 15920 0.00 D Ordinary Shares 15920 15921 D Restricted Share Units 2022-03-04 4 M 0 43358 0.00 D Ordinary Shares 43358 0 D Restricted Share Units 2022-03-04 4 A 0 134048 0.00 A Ordinary Shares 134048 134048 D Restricted Share Units 2022-03-05 4 M 0 22576 0.00 D Ordinary Shares 22576 67728 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on March 4, 2019, with 15,920 having vested on each of March 4, 2021 and March 4, 2022, and 15,921 vesting on March 4, 2023. Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. Restricted share units were granted on March 5, 2021, with 22,576 having vested on March 5, 2022 and 22,576 vesting on each of March 5, 2023, March 5, 2024 and March 5, 2025. /s/ Dov Bergwerk as attorney-in-fact for Richard Daniell 2022-03-08